Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Hannah Smith

Physician Assistant Mobile, AL Physician Assistant

NPI 1962155408 CMS profile 11369944

580 Providence Park Dr E Fl 2, Mobile, AL 36695

Open in the dashboard

General payments

$9,506

483 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hannah Smith of Mobile, AL is reported in the CMS Open Payments database as having received $9,506 across 483 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,076 184
2024 General $3,769 197
2023 General $2,536 97
2022 General $125 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hannah Smith
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Hannah Smith were reported at $3,076. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Hannah Smith Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $125 $155 $48–$522 $149
2023 $2,536 $167 $52–$557 $160
2024 $3,769 $178 $55–$600 $164
2025 $3,076 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $2,150 103 payments
  2. Novartis Pharmaceuticals Corporation $1,071 62 payments
  3. Dermavant Sciences, Inc. $873 22 payments
  4. UCB, Inc. $704 30 payments
  5. Sun Pharmaceutical Industries Inc. $690 41 payments
  6. Incyte Corporation $664 42 payments
  7. Janssen Biotech, Inc. $633 51 payments
  8. Regeneron Healthcare Solutions, Inc. $595 25 payments
  9. Genzyme Corporation $350 18 payments
  10. Lilly USA, LLC $292 10 payments
  11. Other $1,484 79 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $9,215 479 payments
  2. Education $291 4 payments
Products named General payments · program years 2022–2025
  1. RINVOQ $975 43 payments
  2. VTAMA $889 24 payments
  3. COSENTYX $777 47 payments
  4. SKYRIZI Immunology $764 37 payments
  5. Bimzelx $704 30 payments
  6. TREMFYA $633 51 payments
  7. DUPIXENT Immunology $613 25 payments
  8. OPZELURA $595 41 payments
  9. DUPIXENT Inflammation And Immunology $442 18 payments
  10. SKYRIZI Immunology $402 22 payments
  11. Other $2,896 161 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

968

Median for Physician Assistant: 241

Drug cost

$139,833

Median for Physician Assistant: $4,110

Branded share of claims

5.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 29 $117,200
Clobetasol Propionate Generic 134 $5,012
Ketoconazole Generic 175 $3,132
Triamcinolone Acetonide Generic 154 $2,458
Tacrolimus Generic 20 $2,190
Fluocinolone Acetonide Fluocinolone/Shower Cap Brand 26 $1,883
Metronidazole Generic 22 $1,742
Betamethasone Dipropionate Generic 36 $1,064
Tretinoin Generic 20 $1,046
Doxycycline Hyclate Generic 54 $860

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$84,671

Medicare's payments for the services billed

Medicare patients

355

Average age 75

Services billed

2,225

184 women, 171 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 31%
Ischemic heart disease 31%
Chronic kidney disease 24%
Cancer 17%
Depression 17%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VTAMA
  • Dermavant Sciences, Inc. $649
$649 — —
SKYRIZI
  • AbbVie, Inc. $441
$441 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $344
$344 — —
Bimzelx
  • UCB, Inc. $319
$319 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $125
  • SANOFI-AVENTIS U.S. LLC $99
  • GENZYME CORPORATION $54
$278 29 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

483 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record